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The use of antidepressant drugs for the management of chronic pelvic pain has been supported in the past. This study aimed to
evaluate the available evidence for the eﬃcacy and acceptability of antidepressant drugs in the management of urological chronic
pelvic pain. Studies were selected through a comprehensive literature search. We included all types of study designs due to the
limited evidence. Studies were classiﬁed into levels of evidence according to their design. Ten studies were included with a total of
360 patients. Amitriptyline, sertraline, duloxetine, nortriptyline, and citalopram are the antidepressants that have been reported
in the literature. Only four randomized controlled trials (RCTs) were identiﬁed (two for amitriptyline and two for sertraline) with
mixed results. We conclude that the use of antidepressants for the management of chronic urological pelvic pain is not adequately
supported by methodologically sound RCTs. From the existing studies amitriptyline may be eﬀective in interstitial cystitis but
publication bias should be considered as an alternative explanation. All drugs were generally well tolerated with no serious events
reported.
Copyright © 2009 Christos Papandreou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Chronic pelvic pain is a complex, poorly understood health
problem with prevalence rates ranging from 2.7% to 5.7%
[1, 2].
The European Association of Urology deﬁnes chronic
pelvic pain as a nonmalignant pain, perceived in structures
related to the pelvis of either men or women and constant
or recurring over a period of ≥6 months. In all cases there
areoften,associatedwithnegativecognitive,behaviouraland
social consequences [3].
Chronic pelvic pain is better viewed as a functional
syndrome involving multiple sites, aetiologies and mech-
anisms. The International Continence Society has deﬁned
this syndrome as persistent or recurrent episodic pelvic
pain associated with symptoms suggesting lower urinary
tract, sexual, bowel, or gynaecological dysfunction, without
evidence of infection or other obvious pathology [4].
Therefore,concerningtheurologicalsystemitcanbebladder
pain syndrome/interstitial cystitis, urethral pain syndrome,
prostate pain syndrome, scrotal pain, or penile pain syn-
drome [3].
The analgesic properties of antidepressant drugs were
ﬁrst reported 40 years ago, and they are now widely used
for the treatment of chronic and neuropathic pain. Their
eﬃcacy has now been shown in randomized controlled trials
(RCTs), systematic reviews, and meta-analyses [5, 6]. It is
also worth noting that their analgesic eﬀect seems to be inde-
pendent of their antidepressant eﬀect [6]. Several controlled
studies support the eﬃcacy of antidepressants in diﬀerent
chronic pain conditions, but little is known about their
eﬃcacy in chronic pelvic pain [7]. This systematic review
aims to assess the available evidence for the eﬃcacy and
acceptability of antidepressant drugs in chronic urological2 Advances in Urology
pelvic pain and to provide data necessary to design future
trials.
2. Methods
2.1. Search Strategy. We searched PubMed and Embase for
studies in English language published from 1966 to Decem-
ber 2008. We used the following search string: (antidepres-
sants OR amitriptyline OR paroxetine OR ﬂuoxetine OR
duloxetine OR venlafaxine OR imipramine OR desipramine
OR sertraline OR citalopram OR doxepin) AND (chronic
pelvic pain OR interstitial cystitis OR prostatitis OR penile
pain OR urethral pain OR scrotal pain). Additional strategy
for identifying trials included searching the reference list of
the studies included.
2.2. Inclusion and Exclusion Criteria. We included all
randomized-controlled trials, nonrandomized controlled
trials, uncontrolled trials (prospective case series), and
observational studies that retrospectively reviewed medical
charts (retrospective case series). All reviews and studies in
which the pharmacological intervention did not include any
antidepressant agent or included combination of agents were
excluded. The decision of including nonrandomized and
uncontrolled studies was based on the limited number of
controlled trials available. Safety and acceptability issues are
also important in this group of patients. For eﬃcacy analysis
data on chronic pelvic pain management, intensity and
duration of pain were considered. Other outcomes measured
by the authors were also considered.
2.3. Data Extraction and Assessment of Methodological Qual-
ity. Data extraction was performed independently by two
of the authors (CP and PS) and checked by another (DG).
In case of disagreement two senior authors (PS and DG)
reviewed the studies and reached a consensus. We used the
Jadad scale [8] to assess the methodological quality of all
included randomized controlled trials. We did not assess the
methodologicalqualityofuncontrolledtrialsorretrospective
reviews as the evidence resulting from these types of study is
relatively weak and uncertain.
2.4. Classiﬁcation of Study Designs. Firstly we classiﬁed the
retrieved papers into either intervention or nonintervention
studies.
In intervention studies the investigators intentionally
change some aspect of the status of the subject, for example
by introducing a new therapeutic regimen. We further
classiﬁed intervention studies into the following categories:
(a) randomized controlled trial (random allocation of
eligibleandconsentingpatientsintogroupstoreceive
or not to receive the study intervention),
(b) nonrandomized controlled trial (similar to the ran-
domized but without random allocation of patients
to the study and control groups),
(c) consecutive case-series (a prospective clinical study
that includes all eligible patients identiﬁed by the
researchers during the study registration period. The
patients are treated in the order in which they are
identiﬁed. This type of study usually does not have
a control group. A synonym of this study is “open-
label” uncontrolled trial and prospective case-series),
(d) nonconsecutive case series (a prospective clinical
study that includes some, but not all, of the eligible
patientsidentiﬁedbytheresearchersduringthestudy
registration period. This type of study does not
usually have a control group. These studies are also
referred to the literature as prospective case-series),
(e) nonintervention studies in the context of the present
reviewwereconsideredallstudiesthatretrospectively
reviewed medical charts of patients. In these studies
the investigators did not see or examined the patients
but systematically extracted patient data from the
medical charts.
For the deﬁnition of consecutive and nonconsecutive case
series we used the terminology used in the US. National
Cancer Institute Dictionary of terms (http://www.cancer
.gov/dictionary/).
2.5. Levels of Evidence. Based on the study design we
categorized the level of evidence that each paper represented
following theguidelines developed by theAgencyforHealth-
care Research and Quality [9, 10]. We deﬁned ﬁve levels of
evidence:
(i) Level I: Meta-analysis of multiple well-designed ran-
domizedcontrolledtrials(sincewecouldnotidentify
any meta-analysis of randomized controlled trials
related to the study aims, this level was not assessed
in this review),
(ii) Level II: Randomized Controlled trial,
(iii) Level III: Nonrandomized controlled trial (IIIA),
uncontrolled trials, consecutive case series, and non-
consecutive case series (IIIB),
(iv)LevelIV :Retrospectivecaseseriesbasedonsystematic
investigation of medical charts,
(v) Level V: case reports, clinical examples, expert opin-
ions, and so forth, (this type of evidence was not
assessed in this review).
Safety proﬁles and tolerability of the antidepressants
considered are described using a narrative, qualitative,
approach. Adverse eﬀects reported in all trials analyzed in
this review are described.
3. Results
The results of our search strategy are presented in Figure 1.
Ten studies were included in this review and their char-
acteristics are summarized in Table 1 [11–20]. Of these
studies, 4 were RCTs, 4 were consecutive (prospective) caseAdvances in Urology 3
series, 1 non consecutive (prospective) case series and 1
retrospective case series. Five studies investigated the eﬃcacy
of amitriptyline and two studies investigated sertraline. Of
the remaining three studies, 1 investigated nortriptyline, 1
duloxetine, and 1 citalopram.
3.1. Amitriptyline. Van Ophoven et al. [11]c o n d u c t e da n
RCT in 50 patients with interstitial cystitis (IC), who were
randomly assigned to amitriptyline or placebo. Patients
were prospectively treated for 4 months with a self-titration
protocol that allowed them to escalate drug dosage in 25mg
increments in 1-week intervals (maximum dosage 100mg).
The primary outcome measure was the change from baseline
in the O’Leary-Sant Interstitial Cystitis Symptom Index
(ICSI). Changes in intensity of pain and frequency were cho-
sen as secondary outcome parameters. The study was of high
quality according to the Jadad scale (score: 5). Amitriptyline
treatment was associated with a mean reduction in symptom
score of 8.4 compared to 3.5 for the placebo group.
The diﬀerence was statistically signiﬁcant (P=.005) and
perhaps clinically signiﬁcant. Pain and urgency intensity also
improved signiﬁcantly in the amitriptyline group compared
to the placebo group (P<.001). Anticholinergic side eﬀects
were reported by all except 2 patients in the amitriptyline
group (92%) and by 5 patients in the placebo group (21%).
The side eﬀects in the amitriptyline group that occurred at
a greater incidence than in the placebo group were mouth
dryness (79% versus 8%), weight gain (63% versus 8%),
sedation (37.5% versus 12.5%), constipation (45.8% versus
8%), nausea (12.5% versus 0%), blurred vision/diplopia (17
% versus 0%), and erectile dysfunction (4% versus 0%).
Sator-Katzenschlager et al. [12] compared the eﬃcacy
and acceptability of amitriptyline, gabapentin and their
combination in 56 women with chronic pelvic pain in
an open-label, randomized, controlled trial. The primary
outcome measure was the change from baseline in pain
intensity. This study had a low Jadad quality score of
2, since it was unblinded and the authors did not
describe the method they used for the random allocation
of subjects. Doses of amitriptyline and gabapentin were
increased to maximum daily doses of 150mg and 3600mg,
respectively, until suﬃcient pain relief or the occurrence
of side eﬀects. All patients experienced signiﬁcant pain
relief during the observation period (P<.0001). However,
monotherapy with amitriptyline achieved less pain relief
compared to the other two treatment approaches. There
was no signiﬁcant diﬀerence between the groups in the
incidence of severe side eﬀects, requiring discontinuation of
treatment.
Van Ophoven and Hertle [13] evaluated amitriptyline’s
safety and eﬃcacy in interstitial cystitis in a consecu-
tive (prospective) case series that included 94 patients.
Amitriptyline was received following an established self-
titration protocol without a limitation of the maximum
daily dose. Mean treatment duration was 16.5±7.2 months.
T h ep r i m a r yo u t c o m em e a s u r ew a sr e s p o n s ed e ﬁ n e db yt h e
Global Response Assessment questionnaire. Further eﬃcacy
measures included changes in pain and urgency. Overall
response to treatment was observed in 60 patients (64%).
Pain and urgency intensity were improved signiﬁcantly
compared with baseline (P<.05). Side eﬀects occurred in 79
patients (84%). They contributed to the decision to drop out
in 25 of the 29 patients (86%) and they were the primary
reason for drop out despite an initial treatment response in
9. Dry mouth was the most frequent side eﬀect.
Hanno et al. [14] treated 25 patients with interstitial
cystitis in nonconsecutive case series. The initial amitripty-
line dose of 25mg was increased gradually during a 3-
week period to 75mg. The authors evaluated the eﬃcacy
of treatment in reducing pain, daytime urinary frequency,
nocturia. A signiﬁcant improvement in pain and daytime
frequency was reported (P<.05). Nocturia did not improve
signiﬁcantly (P=.235). The adverse eﬀects reported were
drowsiness, dry mouth, and weight gain.
Pranikoﬀ and Constantino [15] reviewed the charts of
22 patients with urinary frequency or genital, pelvic, or
suprabubic pain syndromes. All were treated with amitripty-
line in doses ranging from 25 to 100mg. Eleven patients
became symptom-free, six showed signiﬁcant improvement,
and ﬁve did not respond. Of the nonresponders, four could
not tolerate the medication and one patient did not see any
symptom improvement.
3.2. Sertraline. Engel et al. [16]c o n d u c t e da nR C Ti n
order to assess the eﬃcacy of sertraline in 23 women
suﬀering from chronic pelvic pain. Random assignment was
to either 50mg of sertraline taken twice daily or to the same
regimen of an inactive matching placebo. After 6 weeks,
both groups were switched to single-blind placebo for 2-
weeks. After the washout, subjects on placebo during the
ﬁrst study stage were crossed-over to sertraline for a second
6-week stage, while those on sertraline were crossed-over
to placebo. The primary outcome of interest was pelvic
pain intensity estimated by a Composite Pain Intensity
score. This study had a Jadad quality score of 4, since the
authors did not report the random allocation procedure.
There were no signiﬁcant improvements in pain noted on
sertraline compared to placebo. The authors did not provide
information about side eﬀects.
Lee et al. [17]c o n d u c t e das m a l lR C Ti n1 4m e nw i t h
chronic pelvic pain syndrome. Patients were randomized
to receive in a blind double fashion sertraline 50mg daily
or matched placebo for 13 weeks. After that period both
investigators and patients were unblinded. Subjects initially
randomized to receive sertraline were given the option to
continue this for a further 13 weeks and those receiving
placebo were given the opportunity to cross-over into
sertraline. Prostatic symptom frequency (PSF) and severity
(PSS) scores were completed. The study had a Jadad quality
score of 2, since it was unblinded and the authors did not
report the random allocation procedure. There was no sta-
tistically signiﬁcant diﬀerence between the two groups. The
authors noticed a trend towards sertraline being associated
with an improvement in PSF and PSS scores. The authors
mentioned that sertraline was well tolerated, with no further
information provided about side eﬀects.4 Advances in Urology
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96 potentially relevant articles
identiﬁed according to the search
strategy
82 articles excluded
• Reviews (n = 35)
• N o tr e l e v a n tt ot h es t u d ya i m s( n = 47)
14 articles retrieved in full text
f o rm o r ed e t a i l e de v a l u a t i o n
10 studies included in the review
4a r t i c l e se x c l u d e d
• Case reports (n = 3)
• Combination of drugs (n = 1)
Figure 1: Flow Diagram of the study.
3.3. Nortriptyline. Walker et al. [18] reported ﬁndings from
a consecutive (prospective) case series. A total of 14 women
with chronic pelvic pain were treated with nortriptyline
100mg per day after a 2 week upward titration. The
primary end point was the reduction in pain. At the two-
month evaluation six of the seven women who remained in
treatment were either pain free or reported that their pain
was signiﬁcantly better. The rest 8 women had been dropped
out. The study did not include information on side eﬀects.
3.4. Duloxetine. V a nO p h o v e na n dH e r t l e[ 19]c o n d u c t e da
consecutive (prospective) case series in order to evaluate the
eﬃcacy and tolerability of duloxetine for interstitial cystitis.
A total of 48 women were treated for 2 months following an
uptitration protocol to the target dose of 40mg taken twice
daily. The primary end point was a change in the overall
well-being evaluated by a patient reported Global Response
Assessment. Secondary outcome measures were changes in
pain and urgency. Only 5 responders out of 48 patients
(10.8%) were identiﬁed. Regarding secondary end points,
duloxetine treatment did not result in statistically signiﬁcant
improvement of pain and urgency. The tolerability of the
drug was poor, mainly due to nausea. A total of 17 patients
(35.4%) dropped out of the study exclusively due to side
eﬀects.
3.5. Citalopram. Brown et al. [20] evaluated citalopram’s
eﬃcacy in the treatment of chronic pelvic pain in a
consecutive (prospective) case series that included 14
patients. Citalopram dosage ranged from 20 to 60mg per
d a y .T h ep r i m a r yo u t c o m em e a s u r ew a sc h a n g ei np a i n
severity. The authors also assessed the functional disability
response to citalopram. Pain severity showed a trend towards
improvement on the McGill Intensity Scale (P=.096), but
there was no signiﬁcant diﬀerences on the pain disabil-
ity Index (P=.158). The most commonly adverse eﬀects
reported were headache, dry mouth and abdominal pain.
4. Discussion
The main ﬁnding of this review is that the use of antidepres-
sants in the management of chronic urological pelvic pain
is not supported by an adequate number of well designed
randomized controlled trials.
Amitriptyline and sertraline are the drugs that have been
studied more extensively in chronic urological pelvic pain.
Regarding the ﬁrst, we identiﬁed two RCTs that randomized
106patientsrecruited[11,12]andtwoprospectivecaseseries
with a total of 119 patients [13, 14]. Regarding sertraline,
we identiﬁed two RCTs with a total of 37 patients [16, 17].
According to this review most of the studies conducted so far
are uncontrolled prospective case series.
Van Ophoven’s study [11] with amitriptyline for inter-
stitial cystitis was a high-quality double blind RCT with a
small percentage of dropouts and a considerable number
of patients. Engel’s study [16] with sertraline for chronic
pelvic pain provides good level of evidence, but it is of
lower validity. Lee’s study [17] with sertraline is the only
one which was conducted for chronic prostatitis, but it
has low validity and methodological deﬁciencies. Sator-
Katzenschlager’s RCT [12] comparing amitriptyline with
gabapentin did not include placebo and therefore it is
diﬃcult to evaluate eﬃcacy for amitriptyline.
For nortriptyline, duloxetine, and citalopram only
uncontrolled studies were identiﬁed [18–20]. These studies
have the lowest level of evidence and no ﬁrm conclusions
for the eﬃcacy of these antidepressants agents can be
extracted. Therefore, their use should still be considered as
experimental.8 Advances in Urology
Amitriptyline was found to be eﬀective compared to
placebo in interstitial cystitis. However, we could only iden-
tify a single RCT and therefore it is very likely that
publication bias could oﬀer an alternative explanation.
Regarding acceptability, we found that antidepressants
were generally safe drugs with tolerable side eﬀects. The
withdrawal rates in most studies were not high and the
reported reason for the withdrawal was not relevant to the
side eﬀects. Nonetheless, most of the studies were of short-
term duration and it is not known whether acceptability
would be the same on the long-term. Two amitriptyline
studies were of longer duration [12, 13] and have shown that
long-term use may be well tolerated.
A major problem in evaluating the eﬃcacy of antidepres-
sants in chronic urological pelvic pain is the heterogeneity
of the studies concerning the classiﬁcation of chronic pelvic
pain syndrome. In this review we focused on studies
examining chronic urological pelvic pain. However, some of
the included studies consisted of mixed population in terms
of pain location, such as patients with pain perceived in
gynaecological system.
Antidepressants may be eﬀective in chronic pelvic pain
either by acting directly on the neural mechanisms of pain
or by reducing depressive symptoms that may inﬂuence
the experience of pain or the capacity to cope with the
pain. Regarding the ﬁrst, studies have shown that the spinal
and neuronal pathways are modulated by activation and/or
inhibition of neurons in the periphery, at spinal levels
and at supraspinal regulatory sites. Serotonergic pathways
and receptor mechanisms play a crucial role within this
neuronal network. The antidepressants alleviate symptoms
probably via mechanisms such as blockade of acetylcholine
receptors, inhibition of reuptake of released serotonin and
norepinephrine, and blockade of the histamine H1 receptor
[21].
Regardingtheroleofpsychologicalmorbidity,epidemio-
logical studies of chronic pain have shown the strong associ-
ation between depressive symptoms and experience of pain
in general [22] and chronic pelvic pain in particular [23].
Banks and Kerns have proposed a diathesis-stress framework
to explain the nature of this relationship. According to this
model individuals with a higher “diathesis” for depression
(biologically or genetically determined) are more likely to
develop an actual episode of depression in the presence
of a stressor such as chronic pain. These authors suggest
that the treatment of chronic pain can be improved if
depression is considered an essential part of the patient’s
clinical presentation [24]. This view may have practical
clinical implications since, even if there is little evidence
from randomized controlled trials to routinely recommend
the use of antidepressants in all patients with chronic
pelvic pain syndrome, the presence of comorbid psycho-
logical dimension may increase the likelihood of a positive
outcome.
The best way of studying the eﬀect of antidepressants is
by using carefully designed placebo-controlled double blind
studies. More RCTs of longer duration with larger numbers
of patients suﬀering from chronic urological pelvic pain are
needed. Future studies should include patient subgroups on
the basis of symptom severity or predominant symptom.
It may be advisable to stratify the sample with respect to
the presence or absence of major depression to further
evaluate the eﬃcacy of antidepressants. Studies should also
include measures of disability and coping. Combination or
multimodal therapy with antidepressants and other poten-
tially beneﬁcial agents (e.g., anti-inﬂammatory agents, a-
blockers) that have independent actions should be evaluated
in RCTs. Because a given pharmacologic intervention might
selectively alleviate a symptom while causing adverse eﬀects
or exacerbating other symptoms, future trials should assess
both side eﬀects and overall health-related quality of life by
using validated measures.
5. Conclusions
Antidepressants are safe generally tolerable drugs and may
have a place in the treatment of chronic urological pelvic
pain. Amitriptyline, in particular, may be useful in the
management of interstitial cystitis, but the eﬀect of publi-
cation bias cannot be estimated. For this reason our main
conclusion is that we need further research with adequately
designed RCTs in order to better evaluate the exact role of
antidepressants on chronic urological pelvic pain.
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